Researcher
Benedicte De Winter
- Research Expertise:- Visceral pain - Inflammation - ileus - irritable bowel syndrome - IBS - inflammatory bowel disease - IBD - sepsis - experimental and clinical translational research - medisch vaardighedenonderwijs
- Keywords:VISCERAL PAIN, SEPSIS, IRRITABLE BOWEL SYNDROME, INFLAMMATION, INFLAMMATORY BOWEL DISEASE, Medicine
- Disciplines:Gastro-enterology, Inflammation, Pathophysiology
- Research techniques:- in vivo animal models of IBS, IBD and sepsis - visceromotor response and afferent neuronal activity - motility and sensitivity assays - inflammation measurements - Elisa, flowcytometry - vaardigheden, portfolio, stationsproeven
- Users of research expertise:- research labs - pharmaceutical industry - (bio-, para-) medical schools
Affiliations
- Laboratory Experimental Medicine and Pediatrics (LEMP) (Research group)
Responsible
From1 Oct 2013 → Today - Laboratory Experimental Medicine and Pediatrics (LEMP) (Research group)
Member
From1 Oct 2003 → 30 Sep 2013 - Primary and interdisciplinary care Antwerp (ELIZA) (Research group)
Member
From1 Oct 2003 → 30 Sep 2008
Projects
1 - 10 of 32
- Automation of a mucin mRNA isoform-based biomarker platform to monitor patients with inflammatory bowel diseases.From1 Apr 2024 → TodayFunding: IOF - technology validation in lab
- Crosstalk between MUC13 signalling and the mucosal microbiota in gastric cancer development.From1 Jan 2024 → TodayFunding: Nonprofit institution or equivalents
- REspiratory Virus Repository ANTwerp (ReViRAnt).From1 Jan 2023 → TodayFunding: Flemish Resilience. Government of Flanders Recovery Plan - strengthening R&D
- Turning the understanding of inflammation-related pathology into new biomarkers and treatments using next-generation technologies and high-throughput data mining.From1 Nov 2022 → TodayFunding: BOF - postdoctoral mandates
- A mucin mRNA isoform-based biomarker assay to improve treatment response in patients with inflammatory bowel diseases.From1 Sep 2022 → 31 Aug 2023Funding: IOF - technology validation in lab
- High-end comprehensive GCxGC-QTOF-MS research facility for volatile and semivolatile compounds (GALILEO).From1 Jun 2022 → TodayFunding: FWO Medium Size Research Infrastructure
- Assessing health effects of air pollution by non-invasive exhaled breath analysis (ALERT).From1 Jun 2021 → 31 May 2023Funding: Provinces
- Mucin isoform-microbiome crosstalk shaping the course of COVID-19: a help in patient stratification?From1 Nov 2020 → 31 Oct 2021Funding: FWO Special Call for Covid-19 research projects, BOF - projects
- Study of the mechanisms involved in MUC1/MUC13-induced intestinal barrier disruption during inflammatory bowel diseases: a translational approach.From1 Nov 2020 → TodayFunding: FWO junior postdoctoral fellowship
- Functional characterization of human mast cells and basophils in the pathophysiology of diarrhea-predominant irritable bowel syndrome.From1 Oct 2020 → 30 Sep 2022Funding: FWO fellowships
Publications
1 - 10 of 165
- Novel insights in the clinical evaluation and management of childhood obesity(2024)
Authors: Eline Vermeiren, Stijn Verhulst, Kim Van Hoorenbeeck, Benedicte De Winter, Annelies Van Eyck, Luc Bruyndonckx
Number of pages: 251 - Epidemiological characteristics of a population visiting a patient-centered informative website about irritable bowel syndrome(2023)
Authors: Kathleen Van Malderen, Joris De Man, Benedicte De Winter, Heiko De Schepper
Pages: 17 - 25 - Measuring myeloperoxidase activity as a marker of inflammation in gut tissue samples of mice and rat(2023)
Authors: Nikita Hanning, Joris De Man, Benedicte De Winter
Pages: 1 - 9 - Prevalence, risk factors and diagnostic accuracy of non-invasive tests for NAFLD in people with type 1 diabetes(2023)
Authors: Jonathan Mertens, Jonas Weyler, Eveline Dirinck, Luisa Vonghia, Wilhelmus Kwanten, Laura Mortelmans, Cédric Peleman, Shivani Chotkoe, Maarten Spinhoven, Floris Vanhevel, et al.
Pages: 1 - 12 - Aberrant mucin expression profiles associate with pediatric inflammatory bowel disease presentation and activity(2023)
Authors: Tom Breugelmans, Wout Arras, Lauren-Emma Boen, Eliah Borms, Lisa Kamperdijk, Joris De Man, Els Van de Vijver, Benedicte De Winter, Nicolette Moes, Annemieke Smet
Pages: 589 - 601 - The role of adipose tissue and subsequent liver tissue hypoxia in obesity and early stage metabolic dysfunction associated steatotic liver disease(2023)
Authors: Annelies Van Eyck, Wilhelmus Kwanten, Cédric Peleman, Sanae Makhout, Steven Van Laere, Kim Van Hoorenbeeck, Joris De Man, Benedicte De Winter, Sven Francque, Stijn Verhulst
Pages: 1 - 11 - Self-control training supplementing inpatient multidisciplinary obesity treatment in children and adolescents(2023)
Authors: Tiffany Naets, Eline Vermeiren, Leentje Vervoort, Marijke Ysebaert, Stijn Verhulst, Benedicte De Winter, Luc Bruyndonckx, Ann Tanghe, Ann De Guchtenaere, Sandra Verbeken, et al.
Pages: 1 - 12 - IL-22-activated MUC13 impacts on colonic barrier function through JAK1/STAT3, SNAI1/ZEB1 and ROCK2/MAPK signaling(2023)
Authors: Tom Breugelmans, Wout Arras, Baptiste Oosterlinck, Aranzazu Jauregui, Michaël Somers, Bart Cuypers, Kris Laukens, Joris De Man, Heiko De Schepper, Benedicte De Winter, et al.
Pages: 1 - 25 - Novel insights in bronchopulmonary dysplasia(2023)
Authors: Kristien Vanhaverbeke, Stijn Verhulst, Antonius Mulder, Benedicte De Winter, Kevin Lamote, Kim Van Hoorenbeeck, Annelies Van Eyck
Number of pages: 324 - Exploring the role of transmembrane mucins in intestinal barrier dysfunction in inflammatory bowel diseases(2023)
Authors: Tom Breugelmans, Annemieke Smet, Benedicte De Winter, Heiko De Schepper, Joris De Man
Number of pages: 285
Patents
1 - 9 of 9
- Method for determining the severity and prognosis of rsv infection (Inventor)
- Mucins and isoforms thereof in diseases characterized by barrier dysfunction (Inventor)
- Mucin isoforms in diseases characterized by barrier dysfunction (Inventor)
- Mucins and isoforms thereof in diseases characterized by barrier dysfunction (Inventor)
- Method for determining the severity and prognosis of RSV infection (Inventor)
- Bis(acetamidophenyl) guanidinophenyethylphosphonates for use in the prevention and/or treatment of PAR-related diseases. (Inventor)
- Mucin isoforms in diseases characterized by barrier dysfunction (Inventor)
- Bis(acetamidophenyl) guanidinophenylethylphosphonates for use in the prevention and/or treatment of par-related diseases (Inventor)
- Bis(acetamidophenyl) guanidinophenylethylphosphonates for use in the prevention and/or treatment of par-related diseases (Inventor)
Linked dataset
1 - 1 of 1